HIV Infections Clinical Trial
Official title:
A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex
To study the safety and pharmacokinetics (blood levels) of recombinant human CD4
immunoglobulin (rCd4-IgG) in patients with AIDS or AIDS related complex (ARC) who have
failed or declined therapy with zidovudine (AZT). An additional goal of the study is to
obtain a preliminary indication of the antiviral effects of Cd4-IgG in patients with AIDS or
ARC.
Other approaches in addition to existing treatment of HIV infection need to be evaluated.
One approach may be to block HIV infection by interrupting the assembly of the virus within
the cell or the budding of virus from the membrane of the infected cell. In addition,
blocking the attachment of HIV to its cellular receptor may offer another point of attack.
HIV binds to the CD4 receptor on the target T4 lymphocyte and the envelope glycoprotein of
the virus (gp120) is capable of high affinity binding to CD4. Any agent that prevents the
attachment of gp120 to the CD4 receptor should be able to block virus transmission and
spread. Recently, scientists have succeeded in producing highly purified recombinant soluble
human CD4. Recombinant CD4 is capable of binding to HIV envelope protein (gp120) and
inhibiting HIV infectivity in test tube studies. Potential therapeutic benefit in patients
with HIV infection could be derived from either or both of these biologic effects. In order
to extend the length of time that rCD4 stays in the body, the compound has been modified by
combining it with a human immunoglobulin of the IgG1 class (IgG).
Other approaches in addition to existing treatment of HIV infection need to be evaluated.
One approach may be to block HIV infection by interrupting the assembly of the virus within
the cell or the budding of virus from the membrane of the infected cell. In addition,
blocking the attachment of HIV to its cellular receptor may offer another point of attack.
HIV binds to the CD4 receptor on the target T4 lymphocyte and the envelope glycoprotein of
the virus (gp120) is capable of high affinity binding to CD4. Any agent that prevents the
attachment of gp120 to the CD4 receptor should be able to block virus transmission and
spread. Recently, scientists have succeeded in producing highly purified recombinant soluble
human CD4. Recombinant CD4 is capable of binding to HIV envelope protein (gp120) and
inhibiting HIV infectivity in test tube studies. Potential therapeutic benefit in patients
with HIV infection could be derived from either or both of these biologic effects. In order
to extend the length of time that rCD4 stays in the body, the compound has been modified by
combining it with a human immunoglobulin of the IgG1 class (IgG).
Each patient receives rCd4-IgG at a fixed dose level once weekly by intravenous bolus for 12
weeks. Four patients (two per center) are entered at each dose level starting with the
lowest dose. Dose escalation proceeds until a maximum tolerated dose (MTD) is defined.
AMENDED: Includes, as of 891201, an ancillary study entitled "A Study of Recombinant
CD4-Immunoglobulin G (CD4-IgG) Levels in Cerebral Spinal Fluid after rCD4-IgG is
Administered by Intravenous Bolus in Patients With AIDS and AIDS-Related Complex". This
involves selected patients, at the discretion of the Investigator. AMENDED: 900110 To
increase the dose and frequency of administration of rCD4-IgG, based on preliminary results
of pharmacokinetic analyses from Phase I studies in humans. Each patient receives rCD4-IgG
therapy at a fixed dose level 1x, 2x, or 3x weekly by intravenous bolus for 12 weeks.
Follow-up is extended to 8 weeks. Total target accrual is 25 - 28 weeks. AMENDED: 900824
Extension of the Phase I study of the safety and efficacy of CD4-IgG in patients with HIV
infection. Each patient receives one of two fixed doses by IV bolus injection twice per week
for 12 weeks. 20 to 30 patients to be enrolled. Pharmacokinetics will be evaluated. Clinical
safety and antiviral effects will be assayed.
;
Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |